TALDO1 (transaldolase 1)

2013-07-01   Zachary Oaks , Andras Perl 

Departments of Medicine, Microbiology,, Immunology, Biochemistry, Molecular Biology, Neuroscience, Physiology,, Pathology, SUNY Upstate Medical University, Syracuse, New York, USA

Identity

HGNC
LOCATION
11p15.5
IMAGE
Atlas Image
LOCUSID
ALIAS
TAL,TAL-H,TALDOR,TALH
FUSION GENES

DNA/RNA

Note

Starts at 747432 bp from pter and ends at 765024 bp from pter according to hg19-Feb_2009.
Size: 17593 bases; Orientation: TALDO1 is on the plus strand.

Description

Exons 2 and 3 of TALDO1 contain retrotransposable elements (Banki et al., 1994).

Transcription

TALDO1 has 8 exons and its mRNA is composed of 1319 bp.

Pseudogene

TALDO1P1 (Transaldolase 1 pseudogene 1).

Proteins

Atlas Image
The 3-dimensional structure of transaldolase from Thorell et al., 2000. Image downloaded from http://www.ebi.ac.uk.

Description

Transaldolase (TAL) is a 337 amino acid protein in the non-oxidative phase of the pentose phosphate pathway (PPP) with a predicted mass of 37.55kDa. TAL has an α/β barrel and that includes lysine 142 which is responsible for generating the Schiff base intermediate during sugar phosphate metabolism (Thorell et al.,200). A mass spectrometry based investigation of the acetylome identified TAL acetylation at lysines 286, 269, 321, 219 (Choudhary et al., 2009). It has also been proposed that TAL activity may be affected by phosphorylation (Lachaise et al., 2001).

Expression

TALDO1 is ubiquitously expressed, except in erythrocytes.

Localisation

Cytosol and nucleus (Colombo et al., 1997).

Function

The reversible reaction carried out by TAL is: erythros-4-phosphate+fructose-6-phophateglyceraldehydes-3-phosphate+sedoheptulose-7-phosphate. TAL has been proposed as the rate limiting enzyme in the non-oxidative PPP (Banki et al., 1996; Heinrich et al., 1976; Perl, 2007; Wood, 1985).
Atlas Image
From blast of reference proteins (Refseq) against human Transaldolase (NP_006746.1).

Homology

Using the blastp function within Homo sapiens, the only protein to share homology within humans (a paralog) was sorting nexin 32 (SNX32) with an identity of 36%.
Atlas Image
From blastp of NP_006746.1 against all non-redundant protein sequences.

Mutations

Germinal

Homozygous deletion of Serine 171 due to the loss of 3bp in the TALDO1 sequence results in liver cirrhosis and subsequent carcinogenesis.

Implicated in

Entity name
Hepatocellular carcinoma
Cytogenetics
Deletion of nucleotides 512-514 in TALDO1 resulted in the loss of serine 171 in the TAL protein and subsequent TAL deficiency (Verhoeven et al., 2001; Valayannopoulos et al., 2006). TAL deficiency results in the accumulation of sedoheptulose-7-phosphate and polyols. Further studies into TAL deficiency determined that the deletion of S171 resulted in a complete loss of enzymatic activity and rapid degradation in the proteasome (Grossman et al., 2004). Missense mutations at arginine 192, in which the arginine is mutated to either a histidine or cysteine, also results in loss of TAL activity and liver damage in patients (Verhoeven et al., 2005; Wamelink at al., 2008). In addition to liver damage, renal and cardiac complications are also present in these patients (Verhoeven et al., 2001; Valayannopoulos et al., 2006; Verhoeven et al., 2005; Wamelink et al., 2008).
In a mouse model of TAL deficiency, sperm dysmotility and subsequent male infertility are present (Perl et al., 2006). Furthermore, TAL deficiency results in the development of hepatosteatosis, cirrhosis, and hepatocellular carcinoma in both homozygous TAL knockouts and heterozygous mice relative to C57Bl/6 wild type mice (Hanczko et al., 2009). The pathogenic mechanism of liver damage in TAL deficiency is linked to depletion of NADPH, oxidative stress, and mitochondrial dysfunction (Perl et al., 2011). In TAL deficiency, it has been proposed that oxidative stress is exacerbated by increased aldose reductase activity which generates polyols and depletes NADPH (Perl et al., 2011). Low NADPH diminishes the cells ability to regulate cellular redox and polyols can induce proliferation through JNK/c-Jun (Perl et al., 2011). Thus, TAL deficiency and insufficiency predispose to oxidative stress which promotes liver damage, increased proliferation, and hepatocellular carcinoma.
Entity name
Squamous cell carcinoma of the head and neck
Cytogenetics
3 SNPs in the TALDO1 gene have been associated with different squamous cell carcinoma of the head and neck risk. The conversion of cytosine to either guanine or thymine at 490bp upstream of the origin of replication (rs10794338) was protective against tumorigenesis (Basta et al., 2008). In contrast, the mutation of thymine to adenine at position 1874 (rs3901233) and adenine to cytosine at position 2187 (rs4963163) increase the risk of squamous cell cancer of the head and neck (Basta et al., 2008).

Bibliography

Pubmed IDLast YearTitleAuthors
83006191994Cloning and expression of the human gene for transaldolase. A novel highly repetitive element constitutes an integral part of the coding sequence.Banki K et al
89551441996Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression.Banki K et al
188056522008Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck.Basta PV et al
196088612009Lysine acetylation targets protein complexes and co-regulates major cellular functions.Choudhary C et al
90775321997Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis.Colombo E et al
151154362004Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase.Grossman CE et al
194361142009Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine.Hanczko R et al
100801976Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1) Activities in normal, neoplastic, differentiating, and regenerating liver.Heinrich PC et al
113901812001Relationship between posttranslational modification of transaldolase and catalase deficiency in UV-sensitive repair-deficient xeroderma pigmentosum fibroblasts and SV40-transformed human cells.Lachaise F et al
213766652011Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase.Perl A et al
170031332006Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa.Perl A et al
176131662007The pathogenesis of transaldolase deficiency.Perl A et al
108695572000The three-dimensional structure of human transaldolase.Thorell S et al
170953512006Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease.Valayannopoulos V et al
158772062005A newborn with severe liver failure, cardiomyopathy and transaldolase deficiency.Verhoeven NM et al
183318072008Transaldolase deficiency in a two-year-old boy with cirrhosis.Wamelink MM et al

Other Information

Locus ID:

NCBI: 6888
MIM: 602063
HGNC: 11559
Ensembl: ENSG00000177156

Variants:

dbSNP: 6888
ClinVar: 6888
TCGA: ENSG00000177156
COSMIC: TALDO1

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000177156ENST00000319006P37837
ENSG00000177156ENST00000319006A0A140VK56
ENSG00000177156ENST00000528070E9PM01
ENSG00000177156ENST00000528097F2Z393
ENSG00000177156ENST00000530440E9PKI8

Expression (GTEx)

0
100
200
300
400
500
600
700

Pathways

PathwaySourceExternal ID
Pentose phosphate pathwayKEGGko00030
Pentose phosphate pathwayKEGGhsa00030
Metabolic pathwaysKEGGhsa01100
Pentose phosphate pathway (Pentose phosphate cycle)KEGGhsa_M00004
Pentose phosphate pathway, non-oxidative phase, fructose 6P => ribose 5PKEGGhsa_M00007
Pentose phosphate pathway (Pentose phosphate cycle)KEGGM00004
Pentose phosphate pathway, non-oxidative phase, fructose 6P => ribose 5PKEGGM00007
Biosynthesis of amino acidsKEGGhsa01230
Biosynthesis of amino acidsKEGGko01230
Carbon metabolismKEGGhsa01200
Carbon metabolismKEGGko01200
MetabolismREACTOMER-HSA-1430728
Metabolism of carbohydratesREACTOMER-HSA-71387
Pentose phosphate pathway (hexose monophosphate shunt)REACTOMER-HSA-71336
Integration of energy metabolismREACTOMER-HSA-163685
Insulin effects increased synthesis of Xylulose-5-PhosphateREACTOMER-HSA-163754

References

Pubmed IDYearTitleCitations
170953512006Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease.16
184982452008Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing.14
147023492004ZNF143 mediates basal and tissue-specific expression of human transaldolase.13
176037562007Detection of transaldolase deficiency by quantification of novel seven-carbon chain carbohydrate biomarkers in urine.13
233152162013Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype.11
206008732010Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency.10
210629602011Transaldolase exchange and its effects on measurements of gluconeogenesis in humans.8
183318072008Transaldolase deficiency in a two-year-old boy with cirrhosis.7
201947252010Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients.7
186876842008Replacement of a phenylalanine by a tyrosine in the active site confers fructose-6-phosphate aldolase activity to the transaldolase of Escherichia coli and human origin.6

Citation

Zachary Oaks ; Andras Perl

TALDO1 (transaldolase 1)

Atlas Genet Cytogenet Oncol Haematol. 2013-07-01

Online version: http://atlasgeneticsoncology.org/gene/50613/taldo1